10.7.2017 11:44 | Business Wire
Chugai's Bispecific Antibody "Emicizumab" Global Phase III Data in Patients with Haemophilia A with Inhibitors Published in The New England Journal of Medicine Online
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the data from HAVEN 1 study (NCT02622321) was published in the online version of The New England Journal of Medicine (NEJM) . This global phase III study examined Chugai’s bispecific antibody emicizumab in adults and adolescents 12 years of age or older with haemophilia A with inhibitors. Results of HAVEN 1 study and the interim analysis of HAVEN 2 study (NCT02795767), a global phase III study of emicizumab in paediatric patients with haemophilia A with inhibitors, are presented today at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting in Berlin.
“HAVEN 1 study is the first global phase III study for emicizumab. This important data provides the body of evidence for the upcoming new drug application,” said Chugai’s President & COO, Tatsuro Kosaka. “The interim analysis of HAVEN 2 study showed that emicizumab offers benefit for children as well. Chugai is committed to provide a new treatment option as soon as possible for the disease which may severely affect patients' life.”
Chugai is currently preparing to file the new drug application in Japan for emicizumab based on the data of HAVEN 1 study and the interim analysis of HAVEN 2 study. These data have been filed with the US Food and Drug Administration (FDA) and the European Medicines Agency by Roche. Emicizumab was designated as a Breakthrough Therapy by the FDA for the prophylactic treatment of people who are 12 years or older with haemophilia A with factor VIII inhibitor in September 2015.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
MITSUI-CHEMICALS26.7.2017 04:02 | pressemeddelelse
Mitsui Chemicals Starts Accepting Applications on September 1st for 2018 Mitsui Chemicals Catalysis Science Award
CA-NOMINUM25.7.2017 21:54 | pressemeddelelse
Nominum-led Panel Discussion at BlackHat Focuses on the Agility and Coverage Depth of DNS in Discovering and Blocking New Malware
OR-USB-IMPLEMENTERS25.7.2017 18:02 | pressemeddelelse
USB 3.0 Promoter Group Announces USB 3.2 Update
KSA-MOCI25.7.2017 16:11 | pressemeddelelse
King Salman Appoints Commissions to Develop Al-Ola and Diriyah Gate into Major Tourist Attractions
CA-ANDERSEN-TAX25.7.2017 15:32 | pressemeddelelse
Andersen Global Announces Collaboration with UnityFour and Pistiolis-Triantafyllos & Associates in Greece and Cyprus
JANSSEN25.7.2017 15:31 | pressemeddelelse
Janssen Announces Phase 3 Pivotal Study Results for Darunavir-Based Complete Treatment Regimen
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum